NASDAQ:GUTS Fractyl Health Q3 2026 Earnings Date & Estimates $4.07 +0.04 (+0.99%) As of 03:44 PM Eastern This is a fair market value price provided by Massive. Learn more. Fractyl Health is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, after market closes. The conference call is scheduled for November 10, 2026 at 4:00 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 11, 2026TimeAfter Market ClosesConference Call DateNovember 10, 2026Conference Call4:00 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Fractyl Health in Q3 2026Fractyl Health is expected to post earnings of -$1.4967 per share. In the same quarter a year earlier Fractyl Health reported -$4.20 per share. Fractyl Health last reported on August 10, 2026, posting -$1.44 per share and beating the -$1.62 consensus estimate. Fractyl Health has beaten the consensus EPS estimate in 4 of its last 8 quarters.Consensus EstimatesConsensus EPS-$1.4967Prior-Year EPS-$4.20Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$1.44 (Beat by +$0.18)EPS Beat Rate4 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Fractyl Health Q3 2026 Earnings FAQ When does Fractyl Health report Q3 2026 earnings? Fractyl Health (NASDAQ:GUTS) is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Fractyl Health's Q3 2026 earnings call? Fractyl Health's Q3 2026 earnings conference call is scheduled for Tuesday, November 10, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Fractyl Health? Analysts expect Fractyl Health to post earnings of -$1.4967 per share for Q3 2026. Fractyl Health Earnings HeadlinesPortnoy Law Firm Announces Class Action on Behalf of Fractyl Health, Inc. Investors2 hours ago | globenewswire.comFractyl Health, Inc. (GUTS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit2 hours ago | prnewswire.comMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.October 14 at 1:00 AM | The Oxford Club (Ad)GUTS Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Fractyl Health, Inc. Securities Lawsuit - Contact Levi & KorsinskyOctober 14 at 10:15 AM | prnewswire.comPomerantz Law Firm Announces the Filing of a Class Action Against Fractyl Health, Inc. and Certain Officers – GUTSOctober 13 at 4:30 PM | globenewswire.comGUTS Shareholder Alert: October 20, 2026 Lead Plaintiff Deadline in Fractyl Health, Inc. Securities Class Action - Contact SueWallStOctober 13 at 1:24 PM | globenewswire.comSee More Fractyl Health Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Fractyl Health? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fractyl Health and other key companies, straight to your email. Email Address About Fractyl HealthFractyl Health (NASDAQ:GUTS) is a clinical-stage biotechnology company focused on developing therapies for metabolic diseases, including type 2 diabetes and obesity. The company’s approach is based on targeting the biology of the gastrointestinal system and developing treatments intended to address underlying disease mechanisms rather than relying solely on chronic medication. Fractyl Health’s lead product candidate is Revita, an investigational, minimally invasive endoscopic procedure designed to resurface the duodenal lining. The company has studied Revita in patients with type 2 diabetes and is evaluating its potential to improve metabolic control. Fractyl is also developing a gene therapy platform intended to enable durable, potentially long-term production of metabolic hormones such as GLP-1, with the goal of creating a one-time treatment approach for obesity and related metabolic conditions. Founded in 2015 and headquartered in Lexington, Massachusetts, Fractyl Health conducts clinical-stage research and development for its metabolic disease programs. The company was co-founded and is led by Harith Rajagopalan, M.D., Ph.D., who serves as chief executive officer. Fractyl Health became a publicly traded company in 2024 and trades on the Nasdaq under the symbol GUTS.View Fractyl Health ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American Business Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
